Literature DB >> 15621670

Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis.

J A Sánchez-Brunete1, M A Dea, S Rama, F Bolás, J M Alunda, S Torrado-Santiago, J J Torrado.   

Abstract

An in vivo study has been performed in order to determine the influence of amphotericin B (AMB) molecular organization on the toxicity and activity of this drug in the treatment of experimental visceral leishmaniasis. Three formulations with similar composition but different drug molecular self-association in aqueous media were prepared. Acute toxicity was evaluated by injecting them in healthy hamsters. Sub-acute toxicity and efficacy were studied administering them to animals previously infected with Leishmania infantum. The preparation with drug molecules completely dissolved into monomers (formulation "C") and produced the highest acute toxicity. The formulation whose AMB molecules were disposed as non-water-soluble multi-aggregates (formulation "B") proved to provide the lowest acute toxicity. This formula also showed an improved activity, mainly in the liver, if compared with the third tested formulation containing AMB molecules disposed as smaller dimerical "water-soluble" aggregates (formulation "A"). As a conclusion, molecular aggregation in biological media should be an important factor to consider when researching or optimizing medicines containing AMB. The liberation of molecules as large dispersed non-water-soluble multi-aggregates seems to improve the narrow therapeutic margin attached to the use of this drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15621670     DOI: 10.1080/10611860400006596

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

1.  Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

Authors:  Samusi A Adediran; Timothy P Day; Diptesh Sil; Matthew R Kimbrell; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

2.  Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.

Authors:  Abeer H A Mohamed-Ahmed; Karin Seifert; Vanessa Yardley; Hollie Burrell-Saward; Stephen Brocchini; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

3.  Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Authors:  Shalini Asthana; Anil K Jaiswal; Pramod K Gupta; Vivek K Pawar; Anuradha Dube; Manish K Chourasia
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

4.  Formulation and evaluation of microemulsion based delivery system for amphotericin B.

Authors:  Pradnya S Darole; Darshana D Hegde; Hema A Nair
Journal:  AAPS PharmSciTech       Date:  2008-01-18       Impact factor: 3.246

5.  Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.

Authors:  Qamar Zia; Aijaz Ahmed Khan; Zubair Swaleha; Mohammad Owais
Journal:  Int J Nanomedicine       Date:  2015-03-05

6.  Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.

Authors:  Qamar Zia; Owais Mohammad; Mohd Ahmar Rauf; Wasi Khan; Swaleha Zubair
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

7.  Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity.

Authors:  Yuri Svirkin; Jaeweon Lee; Richard Marx; Seongkyu Yoon; Nelson Landrau; Md Abul Kaisar; Bin Qin; Jin H Park; Khondoker Alam; Darby Kozak; Yan Wang; Xiaoming Xu; Jiwen Zheng; Benjamin Rivnay
Journal:  Asian J Pharm Sci       Date:  2022-06-08       Impact factor: 9.273

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.